CSL’s Hemgenix Gene Therapy Does Not Need A REMS, FDA Tells National Hemophilia Foundation

 
• By Brenda Sandburg
  
Gene therapy
Labeling for hemophilia gene therapy infusion sufficiently conveys risks of its use, US FDA says • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies